In clinical trials under several conditions, PD‐1 and PD‐L1 inhibitors have significantly improved prognostic indicators (OS and PFS) in advanced NSCLC compared with that of conventional anticancer drugs.19, 20, 21, 22. Here, PDCD1 is linked to non-small cell lung carcinoma.